Sun Pharma announces USFDA approval for generic Namenda® tablets	   	Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Sun Pharma announces USFDA approval for generic Namenda® tablets Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.’s Namenda 5 mg and 10 mg tablets.

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

Sun Pharma ended lower at on BSE. The pharma company received a Warning Letter from the US FDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat in India.

India’s largest drugmaker Sun Pharmaceutical Industries Ltd said it had received a warning letter from the US Food and Drug Administration for violating manufacturing standards at its Halol plant in western India. The warning indicates the agency is not satisfied with the remedial measures Sun Pharma has been taking at the plant since last September …

India's largest drug group Sun Pharmaceutical Industries Ltd said on Friday its U. sales might fall this year because of pressure on .

Sun Pharmaceutical Industries Ltd’s southward journey continues for yet another trading session. The scrip is currently trading 1.3% lower at Rs. 709.15 on BSE, which is a 16-month low level. - See more at: http://ways2capital-equitytips.blogspot.in/2015/11/sun-pharma-falls-13-pays-rs-500-cr.html#sthash.7RMIbaax.dpuf

Sun Pharma rallies over after strong numbers : Sun Pharma reported an over two-fold jump in its consolidated net profit to Rs crore for the September quarter.

Here’s a round-up of the stories thus far: Reuters: FDA bans imports from Sun Pharma plant in India crackdown The U.S. Food and Drug Administration (FDA) has banned imports from Indian generic drugmaker Sun Pharmaceutical Industries Ltd’s plant at Karkhadi in the western state of Gujarat, in the latest quality blow for India’s drug sector. …

the FDA just banned all imports from Sun Pharmaceuticals, makers of Modalert

Sun Pharmaceutical Industries Ltd posted a net profit of Rs. 17136.90 million for the quarter ended March 31, 2016 where as the same was at Rs. 8892.40 - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-q4-net-profit-at-rs1713690-mn.html#sthash.V5x4pKck.dpuf

Medical professional’s wits against the genes of bacteria: The world’s newest threat, antibiotic resistant bugs, with the unaffectionate sobriquet ‘superbugs,’ are getting the better of the medical and pharmaceutical fraternity.

10 inspiring business quotes from the top 10 richest people in Asia! \m/ Rank 9 Net worth: $16.4 billion Age: 60 Country: India Industry: Pharmaceuticals Source of wealth: Self-made; Sun Pharmaceutical Industries  #Business #inspiration #motivation #life #quotes #asia #contactdb #databaseprovider #2of10

ContactDB provides quality contact list, email lists and business list for businesses to use in marketing campaigns.

#SunPharmaceutical Industries Ltd wins U.S. approval to buy #Ranbaxy  http://pocketnewsalert.blogspot.in/2015/01/sun-pharmaceutical-industries-ltd-wins.html

India's Sun Pharmaceutical Industries Ltd has won U. approval to buy Ranbaxy Laboratories Ltd on condition

Glaxo to sell Port Fairy plant to Indian buyers. GlaxoSmithKline (GSK) revealed its opiates businesses in Port Fairy and Tasmania's Latrobe would be taken over by Sun Pharmaceutical Industries.

GLAXO has refused to rule out cutbacks at its Port Fairy pharmaceuticals factory as part of a massive global restructure.

Sun Pharmaceutical Industries Ltd announced today the successful completion of its acquisition of InSite Vision Incorporated.

Shares of Sun Pharma were lower by at company posted a net profit after taxes, Minority Interest and Share of Profit/(Loss) of Associates of Rs. mn for the quarter ended September 2015

Drug major Sun Pharmaceutical Industries has said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a whol...

Sun Pharma raises Rs 1,000 cr via NCDs

Drug major Sun Pharmaceutical Industries has said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a whol...

Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines

Sun Pharma Recalls Effexor in U.S.

India's Sun Pharma recalls over bottles of antidepressant ! they dump their "failures" on the so-called third world, just as they've did with tobacco products.

Sun Pharma gains after settling antitrust litigation in US:- 10 July, 2017: Sun Pharmaceutical Industries gained over 2% in the early morning trade on Monday after the company announced that it has settled antitrust litigation in the US.

Drug major Sun Pharmaceutical Industries on Wednesday said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules.

Shares of Sun Pharmaceutical Industries, India’s largest drug maker, are currently trading 0.49% lower at Rs. 794.40 on BSE. The company has singed a global deal with ICGEB for treatment of Dengue. - See more at: http://ways2capital-equitytips.blogspot.in/2016/05/sun-pharma-trades-in-red-despite-deal.html#sthash.DSIxwmGu.dpuf

Shares of Sun Pharmaceutical Industries, India’s largest drug maker, are currently trading lower at Rs. on BSE. The company has singed a global deal with ICGEB for treatment of Dengue.

Intraday Calls For Todays  Sell Sun Pharmaceuticals Industries Ltd at 726.00 for the target of 720.00 with stop loss of 728.00  Buy Dabur India Ltd at above: 293.26 Targets: 297.41 – 301.73 – 306.09 – 310.48 Stop loss : 289  Buy MCX at above: 1278.06 Targets: 1286.37-1295.35-1304.36 – 1313.4 Stop loss :1269.14

Free Trial –Stock Tips, Mcx Market Tips, Commodity Trading Tips, Equity Tips on Mobile: Indian Stock Market Trading Tips and Recommendatio.

Pinterest
Search